Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$33.66
+3.6%
$30.34
$19.80
$35.50
$1.91B0.83801,519 shs857,490 shs
Allakos Inc. stock logo
ALLK
Allakos
$1.13
+7.6%
$1.26
$0.98
$5.64
$100.05M0.821.22 million shs426,682 shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$23.17
+2.4%
$27.72
$20.67
$42.48
$2.87B0.711.43 million shs1.11 million shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$40.18
+3.6%
$50.54
$12.96
$62.21
$3.55B1.181.26 million shs1.64 million shs
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$94.86
+3.9%
$90.85
$43.89
$101.00
$5.81B0.63760,882 shs883,482 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-0.79%+2.17%+11.15%+43.68%+40.15%
Allakos Inc. stock logo
ALLK
Allakos
-4.55%0.00%-16.67%-17.32%-76.35%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-2.20%-4.88%-20.91%-29.53%-36.67%
Biohaven Ltd. stock logo
BHVN
Biohaven
-2.56%-1.99%-29.04%-12.73%+185.79%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-1.89%-1.03%-3.71%+14.85%+77.36%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
1.0624 of 5 stars
1.31.00.04.70.80.80.0
Allakos Inc. stock logo
ALLK
Allakos
4.2757 of 5 stars
3.11.00.04.73.23.31.3
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.5636 of 5 stars
3.31.00.03.41.23.30.6
Biohaven Ltd. stock logo
BHVN
Biohaven
3.6319 of 5 stars
4.51.00.00.03.24.20.6
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.8705 of 5 stars
2.32.00.00.03.00.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.50
Moderate Buy$33.50-0.48% Downside
Allakos Inc. stock logo
ALLK
Allakos
2.20
Hold$1.8362.24% Upside
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.64
Moderate Buy$50.80119.25% Upside
Biohaven Ltd. stock logo
BHVN
Biohaven
3.00
Buy$52.1329.73% Upside
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.50
Moderate Buy$91.57-3.47% Downside

Current Analyst Ratings

Latest BHVN, BPMC, ALLK, ARWR, and AGIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00 ➝ $130.00
4/26/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$110.00
4/26/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$97.00
4/26/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00
4/23/2024
Biohaven Ltd. stock logo
BHVN
Biohaven
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$59.00 ➝ $60.00
4/18/2024
Biohaven Ltd. stock logo
BHVN
Biohaven
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/10/2024
Biohaven Ltd. stock logo
BHVN
Biohaven
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/10/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$114.00
4/9/2024
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/9/2024
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$61.00
3/4/2024
Biohaven Ltd. stock logo
BHVN
Biohaven
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $63.00
(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$26.82M71.25N/AN/A$14.51 per share2.32
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/A$1.93 per shareN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$240.74M11.92N/AN/A$2.68 per share8.65
Biohaven Ltd. stock logo
BHVN
Biohaven
$462.51M7.67N/AN/A$5.34 per share7.52
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$249.38M23.28N/AN/A$2.15 per share44.12

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$352.09M-$6.34N/AN/AN/A-1,312.64%-38.08%-33.69%5/2/2024 (Confirmed)
Allakos Inc. stock logo
ALLK
Allakos
-$185.70M-$2.13N/AN/AN/AN/A-80.23%-62.03%5/14/2024 (Estimated)
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$205.27M-$2.78N/AN/AN/A-163.32%-90.77%-38.56%5/9/2024 (Confirmed)
Biohaven Ltd. stock logo
BHVN
Biohaven
-$408.17M-$5.66N/AN/AN/AN/A-103.50%-80.78%5/10/2024 (Estimated)
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$506.98M-$8.36N/AN/AN/A-203.30%-191.56%-45.25%5/2/2024 (Confirmed)

Latest BHVN, BPMC, ALLK, ARWR, and AGIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06N/A+$0.06N/AN/AN/A  
5/2/2024N/A
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.63N/A+$1.63N/AN/AN/A  
5/2/2024N/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$1.65-$1.66-$0.01N/AN/AN/A  
3/14/2024Q4 2023
Allakos Inc. stock logo
ALLK
Allakos
-$0.53-$0.71-$0.18-$0.71N/AN/A
2/29/2024Q4 2023
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.41-$1.81-$0.40-$1.81N/AN/A
2/15/2024Q4 2023
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.64-$1.72-$0.08-$1.72$7.80 million$7.10 million      
2/15/202412/31/2023
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$2.04-$1.82+$0.22-$1.82$67.34 million$71.96 million    
2/6/2024Q1 2024
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.78-$1.24-$0.46-$1.24$35.60 million$3.55 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
12.27
11.99
Allakos Inc. stock logo
ALLK
Allakos
N/A
4.92
4.92
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/A
3.73
3.73
Biohaven Ltd. stock logo
BHVN
Biohaven
N/A
7.98
7.98
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.60
3.76
3.66

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
Allakos Inc. stock logo
ALLK
Allakos
84.64%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.24%
Allakos Inc. stock logo
ALLK
Allakos
28.07%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
4.50%
Biohaven Ltd. stock logo
BHVN
Biohaven
16.00%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
3.88%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
38356.77 million53.81 millionOptionable
Allakos Inc. stock logo
ALLK
Allakos
13188.54 million63.69 millionOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
525123.90 million118.32 millionOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
23988.26 million74.14 millionOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
65561.20 million58.83 millionOptionable

BHVN, BPMC, ALLK, ARWR, and AGIO Headlines

SourceHeadline
Jackson Creek Investment Advisors LLC Purchases New Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Jackson Creek Investment Advisors LLC Purchases New Stake in Blueprint Medicines Co. (NASDAQ:BPMC)
marketbeat.com - April 30 at 5:34 PM
Blueprint Medicines Co. (NASDAQ:BPMC) Given Average Rating of "Moderate Buy" by BrokeragesBlueprint Medicines Co. (NASDAQ:BPMC) Given Average Rating of "Moderate Buy" by Brokerages
americanbankingnews.com - April 30 at 3:12 AM
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Recommendation of "Moderate Buy" from AnalystsBlueprint Medicines Co. (NASDAQ:BPMC) Receives Average Recommendation of "Moderate Buy" from Analysts
marketbeat.com - April 30 at 2:33 AM
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A BuyRigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
seekingalpha.com - April 29 at 8:38 AM
Federated Hermes Inc. Buys Shares of 24,043 Blueprint Medicines Co. (NASDAQ:BPMC)Federated Hermes Inc. Buys Shares of 24,043 Blueprint Medicines Co. (NASDAQ:BPMC)
marketbeat.com - April 29 at 5:01 AM
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $130.00Blueprint Medicines (NASDAQ:BPMC) PT Raised to $130.00
americanbankingnews.com - April 28 at 2:46 AM
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Reaffirmed by HC WainwrightBlueprint Medicines (NASDAQ:BPMC) Stock Rating Reaffirmed by HC Wainwright
americanbankingnews.com - April 28 at 2:46 AM
Needham & Company LLC Reiterates "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC)Needham & Company LLC Reiterates "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC)
americanbankingnews.com - April 28 at 2:46 AM
Wedbush Reiterates "Outperform" Rating for Blueprint Medicines (NASDAQ:BPMC)Wedbush Reiterates "Outperform" Rating for Blueprint Medicines (NASDAQ:BPMC)
americanbankingnews.com - April 28 at 2:46 AM
State of New Jersey Common Pension Fund D Sells 13,058 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)State of New Jersey Common Pension Fund D Sells 13,058 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
marketbeat.com - April 27 at 8:22 AM
Rubrik to debut on NYSE, IPO priced at $32 per shareRubrik to debut on NYSE, IPO priced at $32 per share
finance.yahoo.com - April 26 at 3:00 PM
Stifel Nicolaus Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $130.00Stifel Nicolaus Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $130.00
marketbeat.com - April 26 at 12:40 PM
Blueprint Medicines (BPMC) "Outperform" Rating Reiterated at WedbushBlueprint Medicines' (BPMC) "Outperform" Rating Reiterated at Wedbush
marketbeat.com - April 26 at 11:16 AM
Blueprint Medicines Corporation: A Strong Buy on Robust Pipeline and Market Potential for Mast Cell Disease TreatmentsBlueprint Medicines Corporation: A Strong Buy on Robust Pipeline and Market Potential for Mast Cell Disease Treatments
markets.businessinsider.com - April 26 at 9:59 AM
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 ExpertsThe Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
markets.businessinsider.com - April 26 at 9:59 AM
Semanteon Capital Management LP Makes New $1.18 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)Semanteon Capital Management LP Makes New $1.18 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)
marketbeat.com - April 25 at 10:36 PM
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseBlueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
zacks.com - April 25 at 11:07 AM
Blueprint Medicines (BPMC) to Release Quarterly Earnings on ThursdayBlueprint Medicines (BPMC) to Release Quarterly Earnings on Thursday
marketbeat.com - April 24 at 6:28 AM
Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)
markets.businessinsider.com - April 22 at 10:20 PM
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Position Trimmed by Raymond James & AssociatesBlueprint Medicines Co. (NASDAQ:BPMC) Stock Position Trimmed by Raymond James & Associates
marketbeat.com - April 22 at 4:09 AM
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
prnewswire.com - April 18 at 8:00 AM
Readystate Asset Management LP Takes $3.69 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)Readystate Asset Management LP Takes $3.69 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)
marketbeat.com - April 17 at 10:38 PM
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Drop in Short InterestBlueprint Medicines Co. (NASDAQ:BPMC) Sees Large Drop in Short Interest
marketbeat.com - April 14 at 5:32 PM
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsBlueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
prnewswire.com - April 11 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Agios Pharmaceuticals logo

Agios Pharmaceuticals

NASDAQ:AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Allakos logo

Allakos

NASDAQ:ALLK
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

NASDAQ:ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Biohaven logo

Biohaven

NYSE:BHVN
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Blueprint Medicines logo

Blueprint Medicines

NASDAQ:BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.